Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLPM-01
- Development stage
- Phase 1
- Lead developer
- VLP Therapeutics
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VLPM-01 is a pre-erythrocytic malaria vaccine candidate developed by VLP Therapeutics. It utilizes a proprietary inserted alphavirus virus-like particle (i-αVLP) platform to deliver the circumsporozoite protein (CSP) antigen of Plasmodium falciparum, the parasite responsible for most cases of severe malaria in humans. The vaccine is adjuvanted with alum (alhydrogel) to enhance immunogenicity. Its mechanism of action is immunostimulation, aiming to induce an immune response that prevents infection at the liver stage before parasites enter red blood cells. Clinical development has included Phase I and II trials assessing safety, immunogenicity, and efficacy using controlled human malaria infection models in healthy, malaria-naïve adults[1][2][3][4][5][7].
- Other names
- VLPM01VLPM-01VLPM 01
02
Targets
CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on VLPM-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLPM-01.